Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)
This study is being done to answer the following question: Can we lower the growth or spread of your advanced cancer by treating you with the combination of the drugs ZEN003694 (ZEN-3694) and talazoparib? We are doing this study because we want to find ou
Why this Research Matters
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to n
Who can Participate
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study.
Study ID
Protocol Number: 23-0145
More information available at ClinicalTrials.gov: NCT05327010
Meet the Team
Principal Investigator